These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 26146750)

  • 1. What Nurses and Patients Need to Know About Sipulecucel-T Immunotherapy for Prostate Cancer.
    Becze E
    ONS Connect; 2015 Jun; 30(2):40-1. PubMed ID: 26146750
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunotherapy: a new option for advanced prostate cancer.
    Harv Mens Health Watch; 2010 Sep; 15(2):1-2. PubMed ID: 20941869
    [No Abstract]   [Full Text] [Related]  

  • 3. Prostate cancer immunotherapy: the role for sipuleucel-T and other immunologic approaches.
    Arlen PM
    Oncology (Williston Park); 2011 Mar; 25(3):261-2. PubMed ID: 21548469
    [No Abstract]   [Full Text] [Related]  

  • 4. Sipuleucel-T for the treatment of advanced prostate cancer.
    Frohlich MW
    Semin Oncol; 2012 Jun; 39(3):245-52. PubMed ID: 22595047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Provenge: combating prostate cancer with a vengeance?
    Schwaab T; Pili R
    Expert Rev Vaccines; 2011 Aug; 10(8):1113-4. PubMed ID: 21854304
    [No Abstract]   [Full Text] [Related]  

  • 6. Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
    Tanimoto T; Hori A; Kami M
    N Engl J Med; 2010 Nov; 363(20):1966; author reply 1967-8. PubMed ID: 21067392
    [No Abstract]   [Full Text] [Related]  

  • 7. Sipuleucel-T shows partial advantage in prostate cancer.
    Gould P
    Lancet Oncol; 2006 Sep; 7(9):710. PubMed ID: 16981300
    [No Abstract]   [Full Text] [Related]  

  • 8. Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.
    Drake CG
    J Natl Cancer Inst; 2012 Sep; 104(18):1422; author reply 1422-3. PubMed ID: 22911668
    [No Abstract]   [Full Text] [Related]  

  • 9. Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.
    Kantoff PW; Higano CS; Small EJ; Whitmore JB; Frohlich MW; Schellhammer PF
    J Natl Cancer Inst; 2012 Jul; 104(14):1107-9; author reply 1109-12. PubMed ID: 22825556
    [No Abstract]   [Full Text] [Related]  

  • 10. Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.
    Gulley JL; Leitman SF; Dahut W; Schlom J
    J Natl Cancer Inst; 2012 Jul; 104(14):1106; author reply 1109-12. PubMed ID: 22825555
    [No Abstract]   [Full Text] [Related]  

  • 11. Putting Provenge in perspective.
    Moul JW
    Oncology (Williston Park); 2011 Mar; 25(3):255, 258. PubMed ID: 21548468
    [No Abstract]   [Full Text] [Related]  

  • 12. Sipuleucel-T in metastatic castration-resistant prostate cancer: profile report.
    Plosker GL
    BioDrugs; 2011 Aug; 25(4):255-6. PubMed ID: 21815700
    [No Abstract]   [Full Text] [Related]  

  • 13. New therapies for castration-resistant prostate cancer.
    Longo DL
    N Engl J Med; 2010 Jul; 363(5):479-81. PubMed ID: 20818868
    [No Abstract]   [Full Text] [Related]  

  • 14. Sipuleucel-T (Provenge): active cellular immunotherapy for advanced prostate cancer.
    McKarney I
    Issues Emerg Health Technol; 2007 Sep; (101):1-4. PubMed ID: 17763575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular immunotherapy licensed for advanced prostate cancer.
    Traynor K
    Am J Health Syst Pharm; 2010 Jun; 67(11):862. PubMed ID: 20484204
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunotherapy for advanced prostate cancer: a novel treatment option to improve survival.
    Peskin SR
    Manag Care; 2011 Sep; 20(9 Suppl 5):3-4, 6-11. PubMed ID: 22046617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Managed care considerations. A new era of advanced prostate cancer management.
    Muller R
    Manag Care; 2011 Sep; 20(9 Suppl 5):5. PubMed ID: 22043721
    [No Abstract]   [Full Text] [Related]  

  • 18. New treatments for metastic prostate cancer.
    Med Lett Drugs Ther; 2010 Sep; 52(1346):69-70. PubMed ID: 20814400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How does sipuleucel-T alter our clinical practice?
    George D
    BJU Int; 2010 Oct; 106(7):945-6. PubMed ID: 20931691
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunotherapy for prostate cancer: walk, don't run.
    Drake CG
    J Clin Oncol; 2009 Sep; 27(25):4035-7. PubMed ID: 19635998
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.